BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $293
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.
BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.
